4-三氟甲基扁桃酸 | 395-35-7

• 物质功能分类: 化学试剂 - 有机试剂 - 芳香酸
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 4-三氟甲基扁桃酸
• 中文别名: 4-(三氟甲基)扁桃酸；对三氟甲基扁桃酸
• 英文名称: 4-(trifluoromethyl)mandelic acid
• 英文别名: 2-hydroxy-2-(4-(trifluoromethyl)phenyl)acetic acid；p-trifluoromethylmandelic acid；D-4-trifluoromethyl-mandelic acid；2-hydroxy-2-[4-(trifluoromethyl)phenyl]acetic acid
• CAS: 395-35-7
• 化学式: C₉H₇F₃O₃
• mdl: MFCD00009724
• 分子量: 220.148
• InChiKey: SDGXYUQKJPFLDG-UHFFFAOYSA-N

物化性质

• 熔点：
  130-134 °C
• 沸点：
  324.2±37.0 °C(Predicted)
• 密度：
  1.3670 (estimate)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.222
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  6

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 安全说明：
  S26,S37/39
• 危险类别码：
  R36/37/38
• WGK Germany：
  3
• 海关编码：
  2918199090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温、密闭保存，并保持干燥。

SDS

Name:	4-(Trifluoromethyl)Mandelic Acid 98% Material Safety Data Sheet
Synonym:	None
CAS:	395-35-7

Section 1 - Chemical Product MSDS Name:4-(Trifluoromethyl)Mandelic Acid 98% Material Safety Data Sheet
Synonym:None

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
395-35-7	4-(Trifluoromethyl)Mandelic Acid	98%	206-900-1

Hazard Symbols: XI
Risk Phrases: 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Irritating to eyes, respiratory system and skin.The toxicological properties of this material have not been fully investigated.
Potential Health Effects
Eye:
Causes eye irritation. May cause chemical conjunctivitis.
Skin:
Causes skin irritation.
Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. The toxicological properties of this substance have not been fully investigated.
Inhalation:
Causes respiratory tract irritation. The toxicological properties of this substance have not been fully investigated. Can produce delayed pulmonary edema.
Chronic:
Effects may be delayed.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes. Wash clothing before reuse.
Ingestion:
Get medical aid. Do NOT induce vomiting. If conscious and alert, rinse mouth and drink 2-4 cupfuls of milk or water. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical device such as a bag and a mask.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic gases may be generated by thermal decomposition or combustion.
Extinguishing Media:
Use agent most appropriate to extinguish fire. Use water spray, dry chemical, carbon dioxide, or appropriate foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills immediately, observing precautions in the Protective Equipment section. Avoid generating dusty conditions.
Provide ventilation.

---

Section 7 - HANDLING and STORAGE
Handling:
Wash thoroughly after handling. Use with adequate ventilation.
Minimize dust generation and accumulation. Avoid contact with eyes, skin, and clothing. Keep container tightly closed. Avoid ingestion and inhalation. Wash clothing before reuse.
Storage:
Store in a tightly closed container. Keep from contact with oxidizing materials. Store in a cool, dry, well-ventilated area away from incompatible substances.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 395-35-7: Personal Protective Equipment Eyes: Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye and face protection regulations in 29 CFR 1910.133 or European Standard EN166.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
A respiratory protection program that meets OSHA's 29 CFR 1910.134 and ANSI Z88.2 requirements or European Standard EN 149 must be followed whenever workplace conditions warrant respirator use.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Powder
Color: white
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 143 - 145 deg C
Autoignition Temperature: Not applicable.
Flash Point: Not applicable.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: CF3C6H4CH(OH)CO2H
Molecular Weight: 220.15

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Stable at room temperature in closed containers under normal storage and handling conditions.
Conditions to Avoid:
Incompatible materials, dust generation, excess heat.
Incompatibilities with Other Materials:
Oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, irritating and toxic fumes and gases, carbon dioxide, hydrogen fluoride gas.
Hazardous Polymerization: Will not occur.

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 395-35-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-(Trifluoromethyl)Mandelic Acid - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Not regulated as a hazardous material.
IMO
Not regulated as a hazardous material.
RID/ADR
Not regulated as a hazardous material.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XI
Risk Phrases:
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 28A After contact with skin, wash immediately with
plenty of water.
S 37 Wear suitable gloves.
S 37/39 Wear suitable gloves and eye/face
protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 395-35-7: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 395-35-7 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 395-35-7 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-三氟甲基扁桃酸 在 氢化铋 氧气 、 溶剂黄146 作用下， 以 二甲基亚砜 为溶剂， 反应 24.0h， 生成 4-三氟甲基苯甲酸
  参考文献：
  名称：

  Bi0/O2 as a New Catalytic System for the Oxidation of α-Ketols, α-Hydroxy Acids and Epoxides

  摘要：

  Bi-0 has been used as a catalyst for the oxidative C-C bond cleavage under O-2 of alpha -ketols, alpha -hydroxy acids and terminal epoxides, to give the corresponding carboxylic acids. The results are compared to those obtained in similar oxidation reactions catalysed by Bi-III carboxylates. These reactions constitute the first example of the catalytic use of Bi-0 in oxidation reactions, and the first evidence for a Bi-III/Bi-0 redox couple under molecular oxygen.

  DOI：

  10.1002/1099-0690(200102)2001:4<735::aid-ejoc735>3.0.co;2-e
• 作为产物：
  描述：

  对三氟甲基苯甲醛 、 二氧化碳 在 (4,4'-di-tert-butyl-2,2'-dipyridyl)-bis-(2-phenylpyridine(-1H))-iridium(III) hexafluorophosphate 、 1,3-二甲基-2-苯基-2H-苯并咪唑 作用下， 以 乙腈 为溶剂， 反应 1.0h， 以74%的产率得到4-三氟甲基扁桃酸
  参考文献：
  名称：

  光催化甲醇阳离子/阴离子Umpolung：将芳香醛和酮直接添加到二氧化碳中

  摘要：

  我们开发了一种新的羰基化合物光催化聚合反应，以生成阴离子甲醇合成子。芳香醛或酮在铱光催化剂和 1,3-二甲基-2-苯基-2,3-二氢-1 H-苯并咪唑 (DMBI) 作为还原剂的存在下与二氧化碳反应，在可见光照射下提供通过将所得的甲醇阴离子与亲电二氧化碳进行亲核加成，生成相应的α-羟基羧酸。

  DOI：

  10.1021/acs.orglett.1c02592

文献信息

• [EN] 2,4-DIAMINOQUINAZOLINES FOR SPINAL MUSCULAR ATROPHY<br/>[FR] 2,4-DIAMINOQUINAZOLINES UTILES POUR LE TRAITEMENT D'UNE ATROPHIE MUSCULAIRE SPINALE
  申请人：DECODE CHEMISTRY INC

  公开号：WO2005123724A1

  公开（公告）日：2005-12-29

  2,4-Diaminoquinazolines of formulae I-IV and VI (I, II, III, IV and VI) are useful for treating spinal muscular atrophy (SMA).

  2,4-二氨基喹唑啉的化学式I-IV和VI（I，II，III，IV和VI）可用于治疗脊髓性肌萎缩症（SMA）。
• Amino acid derivatives
  申请人：AstraZeneca AB

  公开号：US06337343B1

  公开（公告）日：2002-01-08

  There is provided amino acid derivatives of formula I, wherein p, q, R1, R2, R3, R4, Y, n and B have meanings given in the description which are useful as competitive inhibitors of trypsin-like proteases, such as thrombin, and in particular in the treatment of conditions where inhibition of thrombin is required (e.g. thrombosis) or as anticoagulants.

  提供的是公式I的氨基酸衍生物，其中p、q、R1、R2、R3、R4、Y、n和B具有本说明书中给出的含义，它们可用作胰蛋白酶样蛋白酶（如凝血酶）的竞争性抑制剂，特别是在需要抑制凝血酶的情况（例如血栓形成）的治疗中，或者作为抗凝剂。
• Chemoselective esterification of α-hydroxyacids catalyzed by salicylaldehyde through induced intramolecularity
  作者：Shiue-Shien Weng、Hsin-Chun Li、Teng-Mao Yang

  DOI：10.1039/c2ra23068b

  日期：——

  direct and chemoselective esterification of α-hydroxyacids was developed using a reversible covalent-binding strategy. By taking advantage of acetal chemistry, simple aldehydes can be used to efficiently catalyze the esterification of α-hydroxy carboxylic acids in the presence of β-hydroxyacid moieties or other carboxylic acids in amounts equal to or in excess of the alcohols. A diverse array of α-aryl

  使用可逆的共价结合策略开发了一种新的，直接的和化学选择性的α-羟基酸酯化方法。通过利用缩醛化学，可以使用简单的醛在等于或超过醇的量的β-羟基酸部分或其他羧酸的存在下有效地催化α-羟基羧酸的酯化。用10 mol％廉价的市售水杨醛催化的1°和2°醇将各种α-芳基，α-烷基，α-杂芳基和官能化的α-羟基酸平稳地酯化，从而在83-在简单的碱性水溶液处理中除去未反应的羟基酸后，产率为95％。此外，水杨醛可通过真空蒸馏或硅胶纯化回收，从而达到绿色化学标准。机理研究证明，共价加合物的形成III在我们建议的催化循环中（方案1A）负责真正的催化作用。
• 4-Aryl-1,3,2-oxathiazolylium-5-olates as pH-Controlled NO-Donors:  The Next Generation of <i>S</i>-Nitrosothiols
  作者：Dongning Lu、Janos Nadas、Guisheng Zhang、Wesley Johnson、Jay L. Zweier、Arturo J. Cardounel、Frederick A. Villamena、Peng George Wang

  DOI：10.1021/ja0682226

  日期：2007.5.1

  release NO under acidic condition (pH = 5). The decomposition pathway of the aryloxathiazolyliumolates proceeded via an acid-catalyzed ring-opening mechanism after which NO was released and an S-centered radical was generated. Electron paramagnetic resonance (EPR) spin trapping studies were performed to detect NO and the S-centered radical using the spin traps of iron(II) N-methyl-D-glucamine dithiocarbamate

  S-亚硝基硫醇 (RSNO) 是生物系统中一氧化氮 (NO) 的重要外源和内源源。合成了一系列具有不同芳基对位取代基（-CF3、-H、-Cl 和 -OCH3）的 4-aryl-1,3,2-oxathiazolylium-5-olates 衍生物。发现这些化合物在酸性条件下（pH = 5）释放 NO。芳基氧杂噻唑盐的分解途径通过酸催化的开环机制进行，然后释放 NO 并产生 S 中心自由基。使用铁 (II) N-甲基-D-葡糖胺二硫代氨基甲酸酯 [(MGD)2-FeII] 和 5,5- 的自旋陷阱进行电子顺磁共振 (EPR) 自旋捕获研究以检测 NO 和 S 中心自由基二甲基-1-吡咯啉N-氧化物(DMPO)。还，EPR自旋捕获和紫外-可见分光光度法用于分析芳基对位取代对芳基恶噻唑盐的NO释放特性的影响。结果表明，- 等吸电子取代基的存在增强了芳基氧杂噻唑基盐酸盐的 NO 释放能力，而供电子取代基如甲氧基
• [EN] SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1<br/>[FR] PYRIDINES SUBSTITUÉES EN TANT QU'INHIBITEURS DE DNMT1
  申请人：GLAXOSMITHKLINE IP DEV LTD

  公开号：WO2017216726A1

  公开（公告）日：2017-12-21

  The invention is directed to substituted pyridine derivatives. Specifically, the invention is directed to compounds according to Formula (Iar): (Iar) wherein Yar, X1ar, X2ar, R1ar, R2ar, R3ar, R4ar and R5ar are as defined herein; or a pharmaceutically acceptable salt or prodrug thereof. The compounds of the invention are selective inhibitors of DNMT1 and can be useful in the treatment of cancer, pre-cancerous syndromes, beta hemoglobinopathy disorders, sickle cell disease, sickle cell anemia, and beta thalassemia, and diseases associated with DNMT1 inhibition. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting DNMT1 activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

  该发明涉及取代吡啶衍生物。具体而言，该发明涉及符合以下式（Iar）的化合物：（Iar）其中Yar、X1ar、X2ar、R1ar、R2ar、R3ar、R4ar和R5ar如本文所定义；或其药学上可接受的盐或前药。该发明的化合物是DNMT1的选择性抑制剂，可用于治疗癌症、癌前综合征、β血红蛋白病、镰状细胞病、镰状细胞贫血、β地中海贫血以及与DNMT1抑制相关的疾病。因此，该发明进一步涉及包含该发明化合物的药物组合物。该发明还进一步涉及使用该发明化合物或包含该发明化合物的药物组合物抑制DNMT1活性和治疗相关疾病的方法。

表征谱图